Photo from wikipedia
ABSTRACT The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available.… Click to show full abstract
ABSTRACT The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequencing have provided massive amounts of data, revealing the pathogenic mechanism of PCNSL and identifying potential mechanisms for therapeutic exploration. Here, we review targeted drugs that may change the current treatment model of PCNSL.
Keywords:
targeted drugs;
primary central;
relapsed refractory;
central nervous;
nervous system;
refractory primary
Journal Title: Hematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!